TBX1 and neoplasm: Although a large number of preclinical studies have been carried out on CAFs for tumor treatment and some clinical trials are also underway, no CAFs-specific inhibitors have been approved so far, which may be related to the lack of specific targets for CAF and the fact that ongoing clinical trials have not yet been completed.